Mindray Medical plans H-share offering, Hong Kong listing

Shenzhen Mindray Bio-Medical Electronics Co. Ltd. announced on October 14, 2025, that its board approved proposals for an H-share offering and listing on the Main Board of The Stock Exchange of Hong Kong Limited. This move supports the company's internationalization strategy, enhances its global capital operations platform, and bolsters capital strength.

The company plans to complete the offering and listing within 24 months from the shareholders' approval date, or an extended period if agreed. This timeframe considers existing shareholder interests and capital market conditions. The proposal is contingent upon approval by shareholders and various regulatory bodies, including the China Securities Regulatory Commission and Hong Kong financial authorities.

As of the announcement date, specific details beyond the board-approved resolutions remain undetermined. The company cautioned investors that the successful implementation of the H-share offering and listing is subject to significant uncertainty regarding regulatory reviews and approvals. Mindray Medical pledged to provide timely disclosure on future developments.